COCH

+ Watchlist + Portfolio

Envoy Medical, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.74
52-Week Range: $0.36 – $1.89
Market Cap: $57.93M
P/E (TTM): —
EPS (TTM): -0.76
Dividend Yield: —

Advanced Metrics

Price/Book: 15.63
PEG Ratio: —
Return on Equity: —
Return on Assets: -86.53%
Gross Margin: -293.72%
Operating Margin: -10919.61%
Profit Margin: 0.00%
Current Ratio: 1.74
Debt/Equity: 0.22
Total Debt: $810.00K
Free Cash Flow: $-8.22M
Revenue Growth: -34.60%
Earnings Growth: —
Enterprise Value: $39.06M

COCH Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$237.00K	$316.00K	$225.00K	$241.00K
Cost of Revenue	$498.00K	$789.00K	$742.00K	$874.00K
Gross Profit	-$261.00K	-$473.00K	-$517.00K	-$633.00K
Research & Development	$4.97M	$8.96M	$10.18M	$12.49M
Selling, General & Admin	$3.47M	$8.93M	$8.56M	$9.15M
Operating Expenses	$8.45M	$17.89M	$18.74M	$21.64M
Operating Income	-$8.71M	-$18.36M	-$19.26M	-$22.27M
EBITDA	-$8.63M	-$29.79M	-$19.81M	-$21.86M
Pretax Income	-$15.92M	-$29.92M	-$20.80M	-$23.76M
Net Income	-$15.92M	-$29.92M	-$20.80M	-$23.76M
Diluted EPS	-1.57	-2.54	-1.49	-1.23
Diluted Shares	10.15M	12.30M	18.79M	23.26M

COCH Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$183.00K	$4.22M	$5.48M	$3.74M
Receivables	$41.00K	$246.00K	$818.00K	$53.00K
Inventory	$1.29M	$1.40M	$1.71M	$1.55M
Current Assets	$1.65M	$7.46M	$8.90M	$6.28M
Total Assets	$2.56M	$8.27M	$11.54M	$8.56M
Current Liabilities	$2.52M	$7.29M	$7.54M	$11.56M
Long-Term Debt	$33.40M	—	$18.72M	—
Total Debt	$34.53M	$562.00K	$19.66M	$919.00K
Total Liabilities	$38.75M	$10.05M	$30.38M	$20.32M
Retained Earnings	-$225.99M	-$257.26M	-$284.73M	-$313.40M
Shareholders' Equity	-$36.20M	-$1.78M	-$18.84M	-$11.77M
Working Capital	-$871.00K	$171.00K	$1.36M	-$5.28M
Net Debt	$33.66M	—	$13.23M	—

COCH Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$8.80M	-$17.09M	-$17.95M	-$18.20M
Capital Expenditure	-$218.00K	-$153.00K	-$980.00K	-$179.00K
Free Cash Flow	-$9.02M	-$17.24M	-$18.93M	-$18.38M
Depreciation & Amortisation	$75.00K	$133.00K	$173.00K	$302.00K
Stock-Based Compensation	$0.00	$1.57M	$562.00K	$745.00K
Investing Cash Flow	-$218.00K	-$153.00K	-$980.00K	-$179.00K
Financing Cash Flow	$8.09M	$21.28M	$20.20M	$16.63M
Dividends Paid	—	$0.00	-$2.45M	-$1.82M
Net Change in Cash	-$931.00K	$4.04M	$1.27M	-$1.75M

COCH Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$46.00K	$78.00K	$42.00K	$75.00K	$39.00K
Cost of Revenue	$226.00K	$234.00K	$203.00K	$211.00K	$313.00K
Gross Profit	-$180.00K	-$156.00K	-$161.00K	-$136.00K	-$274.00K
Research & Development	$2.75M	$2.48M	$2.70M	$4.55M	$3.64M
Selling, General & Admin	$2.18M	$2.43M	$2.85M	$1.70M	$2.04M
Operating Expenses	$4.93M	$4.91M	$5.55M	$6.25M	$5.68M
Operating Income	-$5.11M	-$5.07M	-$5.71M	-$6.38M	-$5.96M
EBITDA	-$4.44M	-$4.98M	-$5.93M	-$6.51M	-$4.28M
Pretax Income	-$5.00M	-$5.69M	-$6.48M	-$6.59M	-$4.35M
Net Income	-$5.00M	-$5.69M	-$6.48M	-$6.59M	-$4.35M
Diluted EPS	-0.29	-0.32	-0.35	—	-0.08
Diluted Shares	21.33M	21.38M	21.85M	—	68.93M

COCH Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$5.31M	$5.29M	$3.56M	$3.74M	$25.25M
Receivables	$65.00K	$63.00K	$54.00K	$53.00K	$48.00K
Inventory	$1.66M	$1.59M	$1.64M	$1.55M	$1.49M
Current Assets	$8.31M	$7.51M	$5.76M	$6.28M	$27.68M
Total Assets	$10.38M	$9.90M	$8.18M	$8.56M	$29.82M
Current Liabilities	$7.59M	$8.00M	$8.99M	$11.56M	$12.21M
Long-Term Debt	$23.11M	$27.93M	—	—	—
Total Debt	$24.03M	$28.83M	$946.00K	$919.00K	$889.00K
Total Liabilities	$34.61M	$39.76M	$15.71M	$20.32M	$19.27M
Retained Earnings	-$290.97M	-$297.91M	-$305.66M	-$313.40M	-$319.10M
Shareholders' Equity	-$24.22M	-$29.86M	-$7.53M	-$11.77M	$10.55M
Working Capital	$717.00K	-$487.00K	-$3.23M	-$5.28M	$15.47M
Net Debt	$17.79M	$22.64M	—	—	—

COCH Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$3.73M	-$4.46M	-$4.33M	-$5.68M	-$6.06M
Capital Expenditure	-$6.00K	-$1.00K	—	-$172.00K	—
Free Cash Flow	-$3.73M	-$4.46M	-$4.33M	-$5.86M	-$6.06M
Depreciation & Amortisation	$61.00K	$85.00K	$76.00K	$80.00K	$73.00K
Stock-Based Compensation	$160.00K	$146.00K	$324.00K	$115.00K	$283.00K
Investing Cash Flow	-$6.00K	-$1.00K	$0.00	-$172.00K	$0.00
Financing Cash Flow	$3.55M	$4.44M	$2.60M	$6.04M	$27.57M
Dividends Paid	-$1.21M	-$607.00K	$0.00	$1.00K	$0.00
Net Change in Cash	-$177.00K	-$23.00K	-$1.73M	$183.00K	$21.51M

Market Snapshot

About

Envoy Medical, Inc. is a medical device company developing and commercializing implantable hearing solutions for patients with sensorineural hearing loss. Headquartered in St. Paul, Minnesota, the company focuses on innovative cochlear implant technology designed to improve hearing outcomes. Envoy's flagship product, the Acclaim Cochlear Implant System, is designed to be fully implantable and features a rechargeable battery system. The company aims to address limitations of traditional hearing aids and existing cochlear implant technologies through its proprietary platform.